GlassScriptPhysician profile
Afshin Bahador
NPI 1316963713
$701,473.93
in general payments reported to CMS, 2019-2025
35 companies · $182K in 2025
The $182K reported for 2025 was more than what 99% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135K · 2020: $83K · 2021: $34K · 2022: $73K · 2023: $115K · 2024: $81K · 2025: $182K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Education: $90K · Travel and Lodging: $35K · Food and Beverage: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Consulting Fee: $8,111 · Gift: $58.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $206,845.00 |
| Education | $89,900.00 |
| Travel and Lodging | $34,951.79 |
| Food and Beverage | $21,737.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,556.25 |
| Consulting Fee | $8,111.25 |
| Gift | $58.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $445,397.97 | 2019-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $114,252.61 | 2019-2025 | Lynparza |
| Eisai INC. | $55,075.21 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $42,855.55 | 2020 | |
| Mallinckrodt Enterprises LLC | $25,467.77 | 2019 | |
| Applied Medical Resources Corporation | $6,000.00 | 2019 | |
| Heron Therapeutics, INC. | $5,994.68 | 2020-2023 | Zynrelef |
| Merck Sharp & Dohme LLC | $2,260.72 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Glaxosmithkline, LLC. | $886.16 | 2019-2025 | Jemperli, Zejula |
| Clovis Oncology, INC. | $335.58 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $333.64 | 2020-2025 | Precisetumor, Myrisk |
| Tesaro, INC. | $324.76 | 2019 | |
| Coopersurgical, INC. | $305.85 | 2025 | Ally II Ups |
| Biom'Up France Sas | $260.94 | 2020 | |
| Amgen INC. | $187.10 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dysis Medical, INC. | $179.05 | 2019-2021 | |
| Conmed Corporation | $176.11 | 2019-2025 | Airseal |
| Becton, Dickinson and Company | $168.78 | 2024 | Arista Ah Flexitip |
| Coherus Oncology, INC. | $151.56 | 2020-2023 | |
| Foundation Medicine, INC. | $139.30 | 2019-2020 | |
| Pfizer INC. | $130.90 | 2024-2025 | |
| Hologic Sales and Service, LLC | $103.73 | 2024 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Minerva Surgical, INC | $97.00 | 2021 | |
| Abbvie INC. | $73.00 | 2019-2021 | |
| Aroa Biosurgery Incorporated | $55.04 | 2022 | |
| Tactile Systems Technology INC | $51.63 | 2019-2021 | |
| Davol INC. | $47.83 | 2021-2025 | Arista |
| Ethicon US, LLC | $33.03 | 2020-2024 | Ethicon, Stratafix, Echelon Circular |
| Acell, INC. | $28.01 | 2019 | |
| Olympus America INC. | $19.94 | 2023 | |
| Baxter Healthcare | $19.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.71 | 2019 | |
| Seagen INC. | $16.61 | 2022 | |
| Genentech USA, INC. | $15.52 | 2019 | |
| Allergan, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshin Bahador listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.